GADOLIN trial: In follicular lymphoma patients who were refractory to a rituximab-containing regimen

GAZYVA + bendamustine followed by GAZYVA monotherapy more than doubled the median investigator-assessed PFS vs bendamustine alone 1

GAZYVA GADOLIN Secondary Endpoint: investigator-assessed median PFS Chart